About Eyenovia
How micodose array print technology makes it possible.
Overview
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications
Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eyedropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments.
Vision
Eyenovia’s Optejet® dispenser microdose array print technology therapeutics could progress eyecare beyond the standard of traditional eyedroppers to a modern, efficient, effective, precision delivery of ocular pharmaceuticals.
Leadership
Our executive leadership, board of directors, and scientific advisory board members who pilot Eyenovia to innovation. Eyenovia’s leadership is comprised of distinguished and proven members from a multitude of backgrounds.
Who is Eyenovia?
Eyenovia is striving to bring microdosing into all areas of ophthalmology via the Optejet® dispenser, which administers ophthalmic solutions horizontally using our proprietary microdose array print technology. Traditional eyedrops deliver four to five times larger volume than the human eye can actually hold, wasting medication, overdosing the eye with medication and preservatives1. The Optejet® dispenses approximately 8µL of medication to the eye as opposed to the approximately 40µL volume delivered by a traditional eyedropper. Nearly five times less medication is administered with the Optejet®, reducing exposure to drug and preservative by 75-80%, without sacrificing efficacy1. Eyenovia believes the Optejet® will shift the benefit/risk paradigm of drug delivery forward into the future with this innovation.
- American Academy of Ophthalmology (AAO). “Wouldn’t it be great if eyedrops didn’t spill out of your eyes?.” ScienceDaily. ScienceDaily, 13 November 2017
MydCombi (Mydriasis)
MydCombi™ is our proprietary, first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (pupil dilation).
MicroLine (Presbyopia)
MicroLine is our proprietary formulation of microdose pilocarpine and investigational candidate for the episodic treatment of presbyopia.
MicroPine (Myopia)
MicroPine™ is our proprietary microdose formulation of atropine and product candidate for the prevention of progressive myopia (nearsightedness) in children.